New combo therapy offers hope for hard-to-treat rectal cancer
NCT ID NCT06767007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining targeted radiation (SBRT) with an immunotherapy drug (PD-1 antibody) can help people whose rectal cancer has returned and cannot be surgically removed. About 31 adults with a specific type of colorectal cancer will receive the treatment and be followed for at least 2 years. The goal is to see if this approach improves survival and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY RECURRENT RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••